A Canadian cannabis operator announced its plans to pursue an entry into the US with support from a cannabis investment firm.

On Tuesday (October 9), TerrAscend (CSE:TER) revealed its plan to enter the fractured US market through the acquisition of operators in legal cannabis states with therapeutic or recreational portfolios.

Michael Nashat, president and CEO of TerrAscend said in the press release the company is targeting a “tremendous opportunity” for its shareholders in the US market.

Nashat indicated the company plans to grow its business organically through disciplined acquisitions. The model referenced by Nashat has been made popular by a collection of multi state operators of cannabis assets in the US.

Companies like iAnthus Capital Holdings (CSE:IAN), MPX Bioceuticals (CSE:MPX), CannaRoyalty (CSE:CRZ) and Green Thumb Industries (CSE:GTII) have gained the attention from investors who are now looking at the US cannabis market as an area with more significant potential gains than Canada.

These multi-state operators are all raising capital on the Canadian Securities Exchange (CSE) due to its lax stance on the US market compared to its TMX Group counterparts.

In the US, cannabis remains an illegal substance on a federal level under the Controlled Substances Act (CSA), despite the fact several states have legalized its use for medical and even recreational purposes.

Companies on the CSE have been allowed to pursue US operations so long as a regular risk disclosure form is shared with the exchange and shareholders.

TerrAscend holds a Canadian licensed producer (LP), Solace Health, within its portfolio of assets. Recreational product from Solace Health will be paired up with four other 1-gram strains from other producers in a new variety package product set to be sold in Ontario once adult-use sales become legal on October 17.

Solace will be tasked with overseeing the fulfillment and distribution of the new product to Ontario consumers through the new recreational sales plan in the province.

Investment partnership supports TerrAscend’s move

TerrAscend will count with financial support from Canopy Rivers (TSXV:RIV), a cannabis investment firm spin off from Canopy Growth (NYSE:CGC,TSX:WEED).

The relationship between the two companies is set to undergo a reorganization from the original investment deal set to require approval from a shareholder majority.

Due to the restrictions on the Toronto Stock Exchange (TSX) or TSX Venture Exchange (TSXV), both Canopy Growth and Rivers will exchange the current warrants of TerrAscend stock for common shares with equal value that will not have voting or participating power.

These new shares will remain until rule changes are made allowing for the investment in the direct US cannabis market through the legalization of the drug in the country.

Bruce Linton, co-CEO of Canopy Growth and acting CEO of Canopy Rivers, said the company is supportive of the reorganization and will support TerrAscend as it seeks opportunities in what he anticipates will be “the largest cannabis economy in the world.”

Acting as an independent financial advisor, Blair Franklin of Capital Partners stated this proposed reorganization would be “fair” for all shareholders involved.

Investor takeaway

As another company joins the US market, the multi-state operator play gains validation from companies seeking to pick specific entry spots and support valuable cannabis ventures.

The backing from Canopy puts TerrAscend in a unique position compared to other multi-state operators. However fellow LPs Aurora Cannabis (TSX:ACB) and Aphria (TSX:APH) hold potential entries through stake purchasing rights for Australis Capital (CSE:AUSA) and Liberty Health Sciences (CSE:LHS).

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less